Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications

Table 2

Clinical experience with new immunotherapies in Hodgkin lymphoma.

Agent	Mechanism of action	Clinical development status	References
Ipilimumab	Anti-CTL4 Mo Ab	Phase I	[245]
Rituximab	Anti-CD20 Mo Ab	Pilot studies	[246–248]
		Phase II (combined with CT)
90Y-ibritumomab tiuxetan	Anti-CD20	Pilot studies	[249]
	radio-immunoconjugate
Alemtuzumab	Anti-CD52 Mo Ab	Pilot-phase II studies	[250, 251]
Lenalidomide	Immunomodulatory	Phase II	[252–256]
Brentuximab vedotin	Antibody-drug conjugate	Phase II	[ 257, 258]
	(anti-CD30 plus tubulin destabilizer)

Mo Ab: monoclonal antibody. CT: chemotherapy.